featured
Olaparib Plus Trastuzumab for HER2-Positive Advanced Breast Cancer With Germline BRCA1/2 Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Breast
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
Breast 2024 Aug 02;77(xx)103780, JE Alés-Martínez, J Balmaña, P Sánchez-Rovira, FJ Salvador Bofill, JÁ García Sáenz, I Pimentel, S Morales, M Fernández-Abad, A Lahuerta Martínez, N Ferrer, P Zamora, B Bermejo, T Díaz-Redondo, MH López-Ceballos, M Galán, J Pérez-Escuredo, L Calabuig, M Sampayo, JM Pérez-Garcia, J Cortés, A Llombart-CussacFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.